Clinical trials: Parainfluenza
QIAGEN ResPlex II Advanced Panel, Influenza A
Collection and Testing of Respiratory Samples
The study will be conducted using nasopharyngeal swab specimens collected prospectively from individuals suspected of having the signs and symptoms of an acute respiratory tract infection caused by a respiratory virus.
- Conditions
- QIAGEN ResPlex II Advanced Panel, Influenza A, Respiratory Syncytial Virus Infections, Infection Due to Human Parainfluenza Virus 1
- Trial name
- NCT01302418
- Testing
- artus Influenza A/B RT-PCR Test
- Where
- 5 sites in United States
- Volunteers
- 272 people
- Sponsor
- QIAGEN Gaithersburg, Inc
Respiratory Tract Infections
Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses
Respiratory tract infections (RTIs) are prevalence community diseases and is the third leading cause of death worldwide. Rapid diagnosis of RTIs is essential as it drives decision points such as treatment, disposition, and…
- Trial name
- NCT05864118
- Testing
- Respiratory pathogen panel PCR test, COVID-19 antibody test
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of Nebraska
Allogeneic Hematopoietic Stem Cell Recipients, Acute Respiratory Infection
Signature of the Host Response to a Respiratory Viral Infection, in the Prediction of Bronchiolitis Obliterans
Bronchiolitis obliterans (BO) is the well-known manifestation of the chronic pulmonary graft-versus-host disease(GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).
- Conditions
- Allogeneic Hematopoietic Stem Cell Recipients, Acute Respiratory Infection, Parainfluenza Virus (PIV)
- Trial name
- ALLOPIV (NCT04099082)
- Testing
- samples
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Paramyxoviridae Infections, Virus Diseases
Safety of and Immune Response to a Cow/Human Parainfluenza Virus Vaccine (rB/HPIV3) in Healthy Infants, Children, and Adults
Human parainfluenza viruses (HPIVs) are a major health concern in infants and young children under 5 years of age, causing serious respiratory tract disease.
- Trial name
- NCT00366782
- Testing
- rB/HPIV3
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Parainfluenza Virus 2
Safety of a Live Attenuated Human Parainfluenza Virus Type 2 (HPIV2) Vaccine for Adults, Children, and Infants
Human parainfluenza virus type 2 (HPIV2) can result in severe respiratory illness in infants and young children. This study will test the safety of and immune response to an HPIV2 vaccine aimed at infants and children.
- Trial name
- NCT01139437
- Testing
- Standard Dose HPIV2 Vaccine, Low dose HPIV2 vaccine
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Viral Pneumonia
Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection
The goal of this Phase 2 study is to assess the safety, antiviral biomarker responses and efficacy of SNG001 when given to patients requiring invasive mechanical ventilation due to a respiratory virus infection.
- Trial name
- INVENT (NCT06999603)
- Testing
- SNG001
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 11 people
- Sponsor
- Synairgen Research Ltd.
Parainfluenza Infection
DAS181 in Patients With Parainfluenza
Background: Parainfluenza is a virus that can cause infections in people. Most people infected with this virus have mild symptoms including fever, cough, red eyes, or runny nose (a common cold).
- Trial name
- NCT01441024
- Testing
- DAS181
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Paramyxoviridae Infections, Virus Diseases
Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children
Human parainfluenza viruses (HPIVs) are a major health concern in infants and young children under 5 years of age, causing serious respiratory tract disease.
- Trial name
- NCT01021397
- Testing
- rHPIV3cp45
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Volunteers, Influenza Vaccination
A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.
The objective of this study is to evaluate the safety and immunogenicity of different vaccines of hemagglutinin formulations of trivalent influenza vaccine or of a combined respiratory syncytial virus / human metapneumovirus /…
- Conditions
- Healthy Volunteers, Influenza Vaccination, Respiratory Syncytial Virus Vaccination, Parainfluenza Vaccination
- Trial name
- NCT06850051
- Testing
- TIV-HA Vaccine formulation 1 at low dose, TIV-HA formulation 1 at high dose, TIV-HA formulation 2 at low dose
- Where
- 6 sites in Australia
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Sanofi
Ebola Virus Disease
Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein
The purpose of this study is to evaluate the safety, infectivity, and immunogenicity of two doses of the HPIV3/ΔHNF/EbovZ GP vaccine candidate when administered intranasally in healthy adults.
- Trial name
- NCT03462004
- Testing
- HPIV3/ΔHNF/EbovZ GP vaccine
- Where
- 2 sites in United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV-2 Infection
Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults
This Phase 1 clinical trial will evaluate the safety and immunogenicity of an intranasal vaccine candidate, a recombinant, live-attenuated, bovine/human parainfluenza virus vector vaccine expressing the 6-P prefusion-stabilized…
- Trial name
- NCT06026514
- Testing
- B/HPIV3/S-6P
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Syncytial Virus Infections, Parainfluenza Infections
Study to Evaluate MEDI-534 in Healthy Adults
The primary objective of this study is to describe the safety and tolerability of a single dose of MEDI-534 when administered to healthy adult volunteers.
- Trial name
- NCT00111878
- Testing
- MEDI-534
- Where
- 3 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Parainfluenza, Respiratory Viral Infections
A Study to Assess the Safety of Live Intranasal Sendai Virus Vaccine in Children and Toddlers
Croup is an illness of young children that is caused by a virus. With this illness, the child has fever, cough, and hoarseness. Although the illness usually gets better in 2 to 4 days, some children may be admitted to the…
- Trial name
- NCT00186927
- Testing
- Sendai virus vaccine
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- St. Jude Children's Research Hospital
Covid19
Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents
This Phase 1 trial is an open-label trial to evaluate the safety, reactogenicity and immunogenicity of two dosages (10^6 PFU and 10^7 PFU) of intranasal CVXGA1 administered as a single dose in healthy adults age 18-55 years and…
- Trial name
- CVXGA1-001 (NCT04954287)
- Testing
- CVXGA1 low dose, CVXGA1 high dose
- Where
- 4 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- CyanVac LLC
Parainfluenza Virus 3, Human
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
Human parainfluenza virus type 3 (HPIV3) is a major cause of pneumonia and other respiratory diseases in infants and children. This study will evaluate the safety and immune response of an HPIV3 vaccine in infants and young…
- Trial name
- NCT01254175
- Testing
- rHPIV3cp45 Vaccine
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)